Blood biomarkers in the early stage of cerebral ischemia

Maestrini, Ilaria; Ducroquet, A.; Moulin, Solene; LEYS, Didier; Cordonnier, Charlotte; Bordet, Regis

Document type :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1016/j.neurol.2016.02.003

PMID :

26988891

Permalink :

http://hdl.handle.net/20.500.12210/16016

Title :

Blood biomarkers in the early stage of cerebral ischemia

Author(s) :

Maestrini, Ilaria [Auteur]
Ducroquet, A. [Auteur]
Moulin, Solene [Auteur]
LEYS, Didier [Auteur]

Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Cordonnier, Charlotte [Auteur]

Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Bordet, Regis [Auteur]

Journal title :

Revue neurologique

Abbreviated title :

Rev. Neurol. (Paris)

Volume number :

172

Pages :

198-219

Publication date :

2016-03-01

ISSN :

0035-3787

English keyword(s) :

Stroke
Biomarkers
Acute
Cerebral ischemia

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

In ischemic stroke patients, blood-based biomarkers may be applied for the diagnosis of ischemic origin and subtype, prediction of outcomes and targeted treatment in selected patients. Knowledge of the pathophysiology of ...
Show more >In ischemic stroke patients, blood-based biomarkers may be applied for the diagnosis of ischemic origin and subtype, prediction of outcomes and targeted treatment in selected patients. Knowledge of the pathophysiology of cerebral ischemia has led to the evaluation of proteins, neurotransmitters, nucleic acids and lipids as potential biomarkers. The present report focuses on the role of blood-based biomarkers in the early stage of ischemic stroke-within 72h of its onset-as gleaned from studies published in English in such patients. Despite growing interest in their potential role in clinical practice, the application of biomarkers for the management of cerebral ischemia is not currently recommended by guidelines. However, there are some promising clinical biomarkers, as well as the N-methyl-d-aspartate (NMDA) peptide and NMDA-receptor (R) autoantibodies that appear to identify the ischemic nature of stroke, and the glial fibrillary acidic protein (GFAP) that might be able to discriminate between acute ischemic and hemorrhagic strokes. Moreover, genomics and proteomics allow the characterization of differences in gene expression, and protein and metabolite production, in ischemic stroke patients compared with controls and, thus, may help to identify novel markers with sufficient sensitivity and specificity. Additional studies to validate promising biomarkers and to identify novel biomarkers are needed.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T13:03:55Z

Blood biomarkers in the early stage of ... BibTeX CSV Excel RIS

Blood biomarkers in the early stage of ...

BibTeX

CSV

Excel

RIS